Citations - Raspagliesi Francesco

CONCLUSION: Combined model that included clinical pathologic variables plus p53 cannot predict response to NACT. Despite this, NACT remain a safe treatment in chemosensitive patients avoiding collateral sequelae related to chemo-radiotherapy.... Read more
Published on: 2024-03-30
Source: Raspagliesi Francesco
By: Antonino Ditto
CONCLUSION: HPV testing in follow-up is of pivotal importance in women with early glandular lesions undergoing conservative treatment, given its recurrence predictive value. However, women who are high-risk HPV-negative in follow-up with non-usual-type histopathology may represent a sub-population at increased risk of recurrences. Further studies should confirm these findings.... Read more
Published on: 2024-03-28
Source: Raspagliesi Francesco
By: Luca Giannella
No abstract... Read more
Published on: 2024-03-26
Source: Raspagliesi Francesco
By: Mara Mantiero
CONCLUSIONS: Endometriosis-associated ovarian cancer patients had significantly longer disease-free survival and overall survival than non-endometriosis-associated ovarian cancer patients, while the recurrence rate was higher in non-endometriosis-associated ovarian cancer patients.... Read more
Published on: 2024-03-26
Source: Raspagliesi Francesco
By: Umberto Leone Roberti Maggiore
CONCLUSIONS: The incorporation of immunotherapy into the initial treatment for advanced and metastatic endometrial cancer brings about a substantial improvement in oncologic outcomes, especially within the MMRd/MSI-H subset. This specific subgroup is currently a focal point of investigation for evaluating the potential of chemotherapy-free regimens. Ongoing exploratory analyses aim to... Read more
Published on: 2024-03-02
Source: Raspagliesi Francesco
By: G Bogani
CONCLUSIONS: Sentinel node mapping does not negatively impact 5-year outcomes of high-intermediate and high-risk endometrial cancer. Further prospective studies are warranted.... Read more
Published on: 2024-03-01
Source: Raspagliesi Francesco
By: Ilaria Cuccu
CONCLUSION: Trabectedin did not improve median OS and showed a worse safety profile in comparison with physician's choice control chemotherapy.... Read more
Published on: 2024-02-05
Source: Raspagliesi Francesco
By: Domenica Lorusso

Other Resources

Other Citations

Other Citations

News by Specialization

News by Specialization

Videos

Selection of Videos by Specialization

Latest News

Latest News

Translate »